Navigation Links
Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer

Dr. David S. Smith to Head Regulatory and Quality Affairs

DUBLIN, Calif., Aug. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Audrey F. Jakubowski, Ph.D., Chief Regulatory and Quality Officer will retire effective today. Dr. Jakubowski's primary responsibilities have been transitioned to David S. Smith, Ph.D., who earlier this year joined SuperGen as Vice President, Regulatory and Quality Affairs.

"Dr. Jakubowski has been extremely instrumental in guiding and growing SuperGen's regulatory and quality efforts over the years," said Dr. James Manuso, President and CEO. "A valued colleague, Audrey created and nurtured a highly effective organization and approach to regulatory affairs and quality management that the Company will continue under Dr. David Smith's leadership."

Dr. Smith, 52, joined SuperGen in March 2007. Prior to joining SuperGen, Dr. Smith was Senior Director, Regulatory Strategy at Wyeth Consumer Healthcare. His responsibilities included obtaining new product registrations on a global level, US marketed product support, and providing scientific and regulatory guidance to business development initiatives. From 1996 to 2000, Dr. Smith served as Regulatory Affairs Program Director at Roche Pharma. Dr. Smith began his regulatory career in 1987 at Schering-Plough, where he focused on the development and registration of oncology and biotechnology products. During his tenure at Schering-Plough, he concentrated on European Union activities and major markets outside of the U.S. Dr. Smith's training includes a post-doctoral fellowship and research in biochemical genetics at the Roche Institute of Molecular Biology. He received a Ph.D. in pharmacology from Wayne State University School of Medicine, and a B.S. in Biophysics, also from Wayne State University.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit


Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development Tel: (925) 560-2845

Tel: (925) 560-0100

E-mail: E-mail:

SOURCE SuperGen Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. State technology chief endorses IT audit recommendations
2. Fusion 2007: CA chief says IT complexity raises risk
3. Web-Based Learning Developed under new Chief Education Officer
4. BD IMag Human Regulatory T Lymphocyte Separation Set for Isolation of Treg Cells
5. Emergence of Internet video is changing the regulatory landscape
6. To attract investment, convince manufacturers that regulatory reform is real
7. Support Regulatory Change to Boost Wisconsins Biotech Sector
8. A Simple and Rapid Technique to Purify High-Quality Midiprep DNA
9. Generate High-Quality, Directional Plasmid cDNA Libraries
10. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
11. Using the Agilent 2100 bioanalyzer for quality control of protein samples prior to MS-analysis
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... At ... Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist ... has been selected for membership in ARCS Alumni Hall of Fame . ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... it will be hosting a Webinar titled, “Pathology is going digital. Is your ... on digital pathology adoption best practices and how Proscia improves lab economics and ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):